Nikesh Shah

Nikesh Shah is a healthcare and life-sciences operating executive who has moved into angel investing. He holds an engineering degree from Mumbai University and an MBA from the Indian Institute of Management (IIM) Bangalore. Early in his career he held senior roles at Accenture and Infosys, where in his last role he led the Knowledge Process Outsourcing (KPO) business for Infosys in EMEA and served on the management council of Infosys BPO, building experience across sales, client management, program management, and delivery.

From March 2012 to August 2019 he served as Chief Operating Officer of GenePath Dx (GenePath Diagnostics), a next-generation molecular diagnostics startup based in Pune (founded 2008 by Nickhil Jakatdar and Nikhil Phadke, with a focus on oncology, infectious disease, and other clinical diagnostics). As COO he owned corporate strategy and worked with the executive leadership team to identify and execute strategic initiatives. The stub email domain (@genepathdx.com) traces to this tenure; he is no longer operationally at GenePath.

Since roughly 2022 he has been at Indegene, a digital-first life-sciences commercialization company, where he is VP and Global Head of Drug Safety & Pharmacovigilance (having earlier led Corporate Strategy and the Pricing, Reimbursement, Market Access & HEOR practice there). His investing activity began in 2023, layering an angel portfolio on top of this operating career; investor-data aggregators classify him as a seed-stage angel investor focused on healthtech in India.

• Invests at seed stage in Indian startups, typically as one participant in a broader angel/syndicate round rather than as a lead.
• HealthTech / digital health is the visible focus — consistent with two decades in diagnostics, pharmacovigilance, and life-sciences commercialization.
• Brings operator value-add: go-to-market, market access, pricing/reimbursement, program management, and BPO/KPO scaling experience rather than purely financial capital.
• Investing activity is recent (started 2023); no publicly stated written thesis or fixed check-size mandate was found — treat him as a value-added angel who backs founders in domains he knows deeply.